Figure 5 from Long-Lasting Response to Lorlatinib in Patients with ALK-Driven Relapsed or Refractory Neuroblastoma Monitored with Circulating Tumor DNA Analysis

Long-term response to lorlatinib in a patient (patient 4) with refractory ALK p.R1275Q-positive neuroblastoma. A, MIBG or ⁶⁸Ga-DOTATATE scans at the time of diagnosis, after induction of chemotherapy, and after 5 months of lorlatinib treatment. Red arrows denote tumors. B, Levels of ctDNA. C, Plasma methoxy noradrenaline. ND, not detected; URL, upper reference limit (0.7 nmol/L).